Progress in molecularly targeted therapies for acute myeloid leukemia

研究成果: Article査読

1 被引用数 (Scopus)

抄録

Genetic abnormalities including specific point mutations have recently been confirmed by applying comprehensive genome sequencing analyses. Molecular targeting therapies, which focus on the mutated proteins and over-expressed proteins in acute myeloid leukemia (AML) cells, are now being developed in clinical studies and/or based on in vitro analyses. This manuscript summarizes the genetic abnormalities in AML cells and some of the current molecular targeting therapies including FLT3 inhibitors (e.g. AC220; Quizartinib), Polo like kinase 1 (PLK1) inhibitors (e.g. BI-6727; Volasertib), IDH2 inhibitors (e.g. AG-221), and XPO1 inhibitors (e.g. KPT-330; Selinexor).

本文言語English
ページ(範囲)130-138
ページ数9
ジャーナル[Rinshō ketsueki] The Japanese journal of clinical hematology
56
2
DOI
出版ステータスPublished - 01-02-2015
外部発表はい

All Science Journal Classification (ASJC) codes

  • 医学(全般)

フィンガープリント

「Progress in molecularly targeted therapies for acute myeloid leukemia」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル